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Tissue plasminogen activator was purified in high yield from pig heart by immunoaffinity chromatography 
and characterized by analysis of the glycosylation pattern and the N-terminal amino acid sequence. Com- 
parisons with the human enzyme reveals residue exchanges in the A-chain at positions 3 (porcine Arg/hu- 
man Gln) and 5 (Thr/Ile), and in the B-chain at positions 6 (Tyr/Phe), 10 (Thr/Ala) and 20 (Val/Ala). The 
glycosylation pattern for the porcine activator was determined by endoglycosidase treatment followed by 
gel electrophoresis. The A-chain contains a single high-mannose type of N-linked glycan structure and the 
B-chain contains a complex type of oligosaccharide. A similar but not identical pattern has been observed 
for the human activator, purified from melanoma cells. 
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1. INTRODUCTION 
Blood clots formed in the vascular system can be 
dissolved by plasmin. This proteolytic enzyme 
which is present in the blood as an inactive proen- 
zyme, plasminogen, has to be activated by plas- 
minogen activators. Two activators of human 
origin, urokinase (u-PA) and tissue plasminogen 
activator (t-PA) have been structurally character- 
ized [l-9]. They are both serine proteases and ac- 
tivate plasminogen by a single proteolytic cleavage 
[lo]. However, one difference is that t-PA requires 
fibrin in order to be a potent activator [ 11,121, 
whereas u-PA activates plasminogen equally well 
in the absence of fibrin. It has been shown that t- 
PA is the most important plasminogen activator in 
the blood [13]. 
* Correspondence address: Department of Protein 
Chemistry, KabiGen AB, S-112 87 Stockholm, 
Sweden 
The human t-PA molecule has been character- 
ized at both protein [l-5] and DNA levels [6,7]. It 
is synthesized as a single-chain protein which is 
readily cleaved by plasmin or trypsin into a two- 
chain form [14]. The disulfide bonded chains of 
the cleaved molecule are designated A-chain 
(N-terminal, heavy chain) and B-chain (C- 
terminal, light chain). The B-chain harbours the 
active site of the enzyme [2], whereas the non- 
catalytic A-chain mediates fibrin binding and 
possibly other protein-protein interactions. This 
part of the activator contains amino acid sequences 
which are homologous to a number of plasma pro- 
teins (review [ 151). 
However, in many studies the porcine activator 
has been utilized, and for this protein no amino 
acid or DNA sequence data have been presented. 
In the present work we have purified tissue plas- 
minogen activator from pig hearts by the use of 
immobilized antibodies directed against he human 
enzyme. The porcine activator has been character- 
ized by N-terminal amino acid sequence analysis 
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and the glycosylation pattern has been studied by 
the use of endoglycosidases. 
2. MATERIALS AND METHODS 
Tissue plasminogen activator was extracted 
from homogenized and acetone-delipidated pig 
hearts using 0.45 M potassium acetate buffer, pH 
4.2, and was further purified by fractionated am- 
monium sulphate precipitation. A detailed presen- 
tation of these steps in relation to the adsorption of 
t-PA to fibrin is given in [14]. To about 4 1 of the 
dissolved precipitate, representing 15 kg heart 
tissue, an aliquot of 30 g of Sepharose-coupled an- 
tibodies against human melanoma t-PA was add- 
ed. After adsorption and washing, the active 
material was eluted from the gel and was further 
purified by chromatography on arginine-Sepharose 
and on Sephadex G-150 columns. Immunization of 
goats, preparation of chromatographic media and 
purification by chromatography were performed 
as in [2]. 
Fibrinolytic activity was determined using a clot 
lysis assay [14] with urokinase as reference stan- 
dard. Protein concentrations were determined with 
a modified Beckman 120C analyzer after hydro- 
lysis in evacuated tubes with 5.7 M HCl for 24 h at 
110°C. The final product had a specific activity of 
about 220 000 IU/mg (international urokinase 
units), and the purification yield was 60%. Prep- 
arations usually contained a mixture of the single- 
chain and the two-chain forms of the enzyme. 
S-Carboxymethylation was performed with 14C- 
labeled iodoacetate [2], and the single-chain mole- 
cules were separated from the two-chain molecules 
on a Sephadex G-150 column (135 x 1.6 cm) in 
50 mM ammonium bicarbonate, 0.1% SDS. Radio- 
active fractions were analyzed by SDS-polyacryl- 
amide gel electrophoresis [161. Fractions contain- 
ing alkylated single-chain and two-chain forms of 
the activator were concentrated under a stream of 
nitrogen. Liquid-phase sequencer degradations 
were performed in a Beckman 89OD instrument, 
and phenylthiohydantoin derivatives were analyzed 
by reverse-phase high-performance liquid chroma- 
tography [17] using a Hewlett-Packard 1090 
instrument. 
Different samples of about 100 pg S-carboxy- 
methylated material (mixture of single and two- 
chain forms) were treated with endo-D-N-acetyl- 
glucosaminidases F (400 mu) and H (1.5 mu), 
respectively. The enzymes were from New England 
Nuclear and reactions were performed in buffers 
recommended by the supplier. Deglycosylation 
was monitored by SDS-polyacrylamide gel elec- 
trophoresis [ 161. 
3. RESULTS AND DISCUSSION 
3.1. Purification 
The four-step purification procedure used in this 
work employed: 1, ammonium sulfate precipita- 
tion; 2, immunoadsorption; 3, arginine-Sepharose 
chromatography; 4, size xclusionchromatography. 
It compares favourably with the five-step fibrin 
adsorption procedure used before [ 141. Utilizing 
the same assay method, specific activity is slightly 
lower in the four-step immunoadsorption method, 
220000 IU/mg compared with 260000 IU/mg, but 
purification yield is significantly better. We now 
obtain a yield of 60% over the four steps, whereas 
the five-step procedure gives a yield of about 25%. 
Thus, by taking advantage of the immunological 
cross-reactivity of t-PA from different species 
(man and pig), immunoadsorption media can be 
prepared, with high enough affinity to specifically 
adsorb the activator, but with low enough affinity 
to allow elution in high yield. 
3.2. N-terminal sequence analysis 
For the single-chain material, one major se- 
quence was obtained and the N-terminal 20 resi- 
dues were identified (table 1). Also seen was a 
clearly minor amino acid sequence derived from 
the B-chain, indicating that the material contains 
about 15% of the two-chain form. When the two- 
chain material was analyzed, the same two se- 
quences were found, but now in equal yield. By 
combining these results we could identify the first 
20 residues of both the A- and the B-chain and 
compare the sequences with the corresponding 
parts of the human enzyme. 
3.3. Comparison with the human tissue 
plasminogen activator 
As expected, the amino acid sequences obtained 
for the porcine activator are highly homologous to 
corresponding parts of the human protein. The 
two-chain porcine t-PA has apparently been 
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Amino acid sequence analyses of single-chain and two-chain forms of porcine tissue plasminogen activator 
Chain Sequence 
1 2 3 4 5 6 I 8 9 10 11 12 13 14 15 16 17 18 19 20 
Ser-Tyr-Arg-Val-Thr-Cys-Arg-Asp-Glu-Lys-Thr-Gln-Met-Ile-Tyr-Gln-Gln-His-Gln-Ser 
Single-cham form (27) (38) (22) (26) (18) 
A-chain of two-cham 
form (17) (23) (19) (10) (9) 
Ile-Lys-Gly-Gly-Leu-Tyr-Ala-Asp-Ile-Thr-Ser-His-Pro-Trp-Gln-Ala-Ala-Ile-Phe-Val 
B-chain of two-cham 
form (13) (16) (15) (19) (2.0) (8) (13) (5) (7) (7) 
Residues were Identified by high-performance liquid chromatography, and recoveries in nmol of stable derivatives are shown within 
parentheses. The two-chain preparation showed two sequences in equal yield, and assignments of residues to A- and B-chains were 
done by comparison with the smgle-chain form 
The two residues which differ among the first 20 
residues in the A-chain were found at positions 3 
and 5 (table 2). The exchanges observed in the B- 
chain (i.e. positions 6, 10 and 20) between human 
and porcine activator apparently occur in a do- 
main where residue exchanges are common be- 
tween species (table 3). However, the residues at 
positions 3, 4, 13 and 14 are identical in all of the 
eight enzymes shown in table 3, relating them to 
each other and to serine proteases in general. The 
residues at these positions are highly conserved in 
the serine protease family. 
For the 10 positions where species differences 
occur, only one position (pos. 20) shows variations 
in all three enzymes, whereas 7 positions have 
species variations unique for t-PA, u-PA or plas- 
Table 2 
Residue differences found between porcine and human 
tissue plasminogen activator for segments l-20 of both 
the A- and B-chain 
Chain Position Porcine 
activator 
Human 
activator 
A 
A 
B 
B 
B 
3 Arg 
5 Thr 
6 Tyr 
10 Thr 
20 Val 
Gin 
Be 
Phe 
Ala 
Ala 
min. The fact that species variations preferably oc- 
cur at unique and different positions for related 
proteins may reflect their functional differences. 
Interestingly, the lysine residue at position 2 in 
the B-chain of human t-PA was also found in the 
porcine enzyme. As suggested before [2], a positi- 
vely charged residue at this position may force the 
single-chain zymogen-like enzyme into a confor- 
mation similar to the active two-chain form. This 
may explain the unusually high reactivity of the 
single-chain form of both porcine and human t-PA 
[23,24] with low-M, substrates and inhibitors as 
compared with other serine protease zymogens. In- 
deed, t-PA is unique in this group of enzymes in 
having a positively charged residue at position 2 of 
the B-chain. 
3.4. Glycosylation pattern 
When the S-carboxymethylated two-chain human 
melanoma t-PA was analyzed by SDS-polyacryl- 
amide gel electrophoresis the A-chain migrated as 
a doublet, whereas the B-chain appeared as a single 
band on the gel [2]. Endoglycosidase treatment of 
this material [25] has shown that the A-chain size 
heterogeneity is caused by a complex type of N- 
linked glycan, present only in the variant I [26] of 
the melanoma activator. In the A-chain of both 
variants I and II a high-mannose glycan structure 
is located, and in the B-chain a complex type of 
oligosaccharide. 
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Table 3 
Comparison of N-terminal sequences from the B-chains of tissue plasminogen activator (t-PA), urokinase (u-PA) and 
plasmin (pli) 
Enzyme 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 References 
t-PA (porcine) I KGGLOAD I@SHPWQAA I F@ thiswork 
t-PA (human) IKGGL@ADI@SHPWQAAIF@ 2 
u-PA (porcine) I~GG@@T@~ENQPWFAAIY@ 18 
u-PA (human) I@GG@@T@aENQPWFAAIY@ 9 
u-PA (murine) I@GG@@T@@ENQPWFAAIY@ 17 
pli (porcine) @ V G G C V @ @ P H S W P W Q @ S L R @ 22 
pli (human)@VGGCV@@PHSWPWQ@SLR@ 21 
pli (bovine) @VGGCV@@PHSWPWQO~LR@ 20 
One-letter codes are used and residues which differ between species for the same enzyme are encircled 
cleaved (before or during purification) at the same 
site as the human enzyme when treated with 
plasmin or trypsin. The N-terminal three residue 
extension seen in the single-chain. human 
melanoma t-PA [2,3] was not observed for the por- 
cine activator, neither the truncated form present 
in t-PA from human uterus [5]. 
No A-chain size heterogeneity was observed for 
the alkylated porcine activator (fig. 1, lanes 1 and 
5). Treatment of this porcine material (mixture of 
single-chain and two-chain forms) with endoglyco- 
sidase F resulted in a size reduction for both the A- 
chain and the B-chain (fig. 1, lanes 5-8), indicating 
that each of the two chains carries an N-linked 
oligosaccharide. Endoglycosidase F has the ability 
to cleave off all types of N-linked glycans [27], 
whereas endoglycosidase H is more specific, cleav- 
ing only high-mannose types of structures [28]. 
Treatment of the porcine activator with endoglyco- 
sidase H resulted in a size reduction only for the A- 
chain (fig.1, lanes l-4), showing that the A-chain 
contains a high-mannose type of glycan structure. 
Some deglycosylation of the B-chain was ob- 
served for the endoglycosidase H treated samples 
(fig.1, lanes l-4). It could be due to heterogeneity 
in the B-chain glycans, or to the presence of less 
specific glycosidases in the endoglycosidase H 
preparation. After treatment with endoglycosidase 
F for 16 h (fig.1, lane 8) some weakly stained 
bands were observed in the gel at sizes about it4, 
13 000, 30 000 and 60 000. These protein bands are 
probably the results of contaminating protease ac- 
Fig. 1. SDS-polyacrylamide gel electrophoresis of S- 
carboxymethylated porcine tissue plasminogen activator 
after treatment with endoglycosidases H and F. Samples 
of 1OOpg of the alkylated protein (mixture of single- and 
two-chain forms) were treated with endoglycosidase H 
and F (1.5 and 400 mu, respectively) at 37°C. Aliquots 
were taken at the times indicated and boiled for 5 min in 
2% SDS to stop the reaction. Electrophoresis was per- 
formed on a 10% slab gel [16] which was stained with 
Coomassie brilliant blue. The positions of the untreated 
A- and B-chains are indicated. The material which was 
treated with endoglycosidase H is shown in lanes 2-4 and 
the corresponding sample treated with endoglycosidase 
F is shown in lanes 6-8. Molecular mass markers (Da) in 
lane 9 are ovotransferrin (77000), albumin (66200), 
ovalbumin (45 000), carbonic anhydrase (30000), 
myoglobin (17 200) and cytochrome c (12 300). 
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tivity in the endoglycosidase F preparation. (81 
The results show that porcine t-PA contains at 
least two N-linked glycan structures. The A-chain 
has a high-mannose type, and the B-chain a com- 
plex type of oligosaccharide. This is very similar to 
the glycosylation pattern observed for the human 
melanoma t-PA. However, in the melanoma t-PA 
a third glycan is present on about 50% of the 
molecules [25] causing the variant I and II hetero- 
geneity [26]. This heterogeneity is not observed in 
the porcine activator studied in this work. 
191 
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